Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial. [electronic resource]
Producer: 20141231Description: 178-85 p. digitalISSN:- 1615-2573
- Adiponectin -- blood
- Aged
- Angina, Stable -- blood
- Angiotensin II Type 1 Receptor Blockers -- therapeutic use
- Anti-Inflammatory Agents -- therapeutic use
- Biomarkers -- blood
- C-Reactive Protein -- metabolism
- Coronary Artery Disease -- blood
- Coronary Vessels -- drug effects
- Disease Progression
- Down-Regulation
- Female
- Humans
- Imidazoles -- therapeutic use
- Inflammation Mediators -- blood
- Japan
- Male
- Middle Aged
- Percutaneous Coronary Intervention
- Plaque, Atherosclerotic
- Prospective Studies
- Tetrazoles -- therapeutic use
- Time Factors
- Treatment Outcome
- Ultrasonography, Interventional
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.